NeoGenomics Inc (NeoGenomics) is a cancer diagnostics and pharma company that offers diagnostic, prognostic and predictive testing services. The company offers testing services with various technologies including cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry and molecular genetics including Sanger sequencing and fragment analysis. NeoGenomics cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases and fluorescence. Its in-situ hybridization testing services for detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes. The company also provides biopharma services which support drug development programs from early biomarker discovery to clinical trials. It serves oncologists, pathologists, pharmaceutical companies and academic centers, among others. NeoGenomics is headquartered in Fort Myers, Florida, the US.
Headquarters
United States of America
Address
9490 Neogenomics Way, Fort Myers, Florida, 33912
Website
neogenomics.com
Telephone
1 239 7680600
No of Employees
2,100
Industry
Medical Equipment
Ticker Symbol & Exchange
NEO (NASD)
Revenue (2022)
$591.6M
16.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
39%
(2022 vs 2021)
Market Cap*
$1.8B
Net Profit Margin (2022)
XYZ
47.5%
(2022 vs 2021)
* As of and is in US$
NeoGenomics Inc premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| Diagnostic | FLEXREPORT |
| Methodologies | HEMEFISH |
| Anatomic Pathology | NeoLAB |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company and ConcertAI, LLC entered into a partnership to advance the field of hematological research. |
| 2023 | Contracts/Agreements | In March, the company and Massive Bio announced a collaboration for development of new cancer therapies. |
| 2023 | New Products/Services | In March, the company announced the commercial availability of multiple tests including Neo Comprehensive - Solid Tumor and Neo Comprehensive - Myeloid Disorders. |
Competitor Comparison
| Key Parameters | NeoGenomics Inc | Myriad Genetics Inc | Enzo Biochem Inc | Net Medical Xpress Solutions Inc | Genomic Health Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Fort Myers | Salt Lake City | Farmingdale | Albuquerque | Redwood City |
| State/Province | Florida | Utah | New York | New Mexico | California |
| No. of Employees | 2,100 | 2,700 | 179 | 19 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Christopher Smith | Chief Executive Officer; Director | Executive Board | 2022 | 60 |
| Jeffrey Sherman | Chief Financial Officer | Senior Management | 2022 | 57 |
| Greg Sparks | Chief Technology Officer | Senior Management | - | - |
| Kathryn McKenzie | Chief Risk Officer; Chief Sustainability Officer | Senior Management | 2022 | - |
| Hutan Hashemi | Chief Compliance Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward